Abbott has put the ball back in Serena Williams’ court to serve up a high-profile endorsement of the Lingo over-the-counter glucose sensor.

AC Immune’s active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson’s disease, after disappointments in earlier trials.

Pfizer’s Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.

Zealand Pharma is spending at least $20 million upfront to discover and develop new targets for metabolic diseases together with Shanghai-based biotech OTR Therapeutics. The deal is part of the Danish drugmaker’s new plans …

As the biopharma industry moves into the next generation of anti-obesity medications, long-acting treatments have become one of the focal points. Prolynx, a biotech 15 years in the making, wants to get in on the …

Biotech hit rock bottom last spring as DOGE ran rampant and President Donald Trump beat the drum for historic tariffs. So for our second-half survey of biotech execs, largely CEOs, we dove right into the …

One of the most closely watched obesity assets in the clinic, Lilly’s triple-G agonist retatrutide, caused patients with obesity and knee osteoarthritis to lose an average of 23.7% of their body weight at around 16 …

Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?

After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the top spot at an obesity-focused biotech.

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.